脐尿管癌具有恶性程度高、预后差、诊断时已属晚期等特点。临床缺乏统一的治疗指南。我们对我中心脐尿管癌的特点、治疗及转归进行总结，希望能为诊治提供参考。我们回顾性分析了我中心2010年1月至2022年8月收治的21例脐尿管癌患者的临床资料。所有患者均获得随访。平均生存时间为67.1±9.1（49.3～84.9）个月。平均无复发生存期为 48.8 ± 9.9（范围为 29.5 至 68.2）个月。六名患者接受了辅助治疗，主要是化疗。 5例患者在随访期间死亡。早期体检可能有助于早期发现脐尿管癌。对于局限性脐尿管癌，手术治疗仍然是首选。淋巴结清扫可能有助于准确分期，切缘阳性通常导致预后较差。辅助治疗，主要是化疗，可能有助于改善预后。放疗、靶向治疗、免疫治疗的应用仍需进一步探索。 Karger AG，巴塞尔。

Urachal carcinoma is characterized by high malignancy, poor prognosis, and late stage of diagnosis. There is a lack of unanimous clinical treatment guidelines. We summarize the characteristics, treatment and outcomes of urachal carcinoma from our center, hoping to provide a reference for diagnosis and treatment.We retrospectively analyzed the clinical data of 21 patients with urachal carcinoma who were treated at our center from January 2010 to August 2022, and all patients were followed up.The average survival time was 67.1 ± 9.1 (ranging from 49.3 to 84.9) months. The average relapse free survival was 48.8 ± 9.9 (ranging from 29.5 to 68.2) months. Six patients received adjuvant therapy, mainly chemotherapy. Five patients died during follow-up.Early physical examination may be helpful for early detection of Urachal carcinoma. Surgical treatment is still preferred for localized urachal carcinoma. Lymph node dissection may facilitate accurate staging, and positive margin usually results in a worse prognosis. Adjuvant therapy, mainly chemotherapy, may help to improve the prognosis. The application of radiotherapy, targeted therapy and immunotherapy still needs further exploration.S. Karger AG, Basel.